Investigation of the Effect of NNC0174-0833 on Pharmacokinetics of an Oral Combination Contraceptive (Ethinylestradiol and Levonorgestrel) in Females of Non-childbearing Potential
Latest Information Update: 11 Jan 2022
At a glance
- Drugs Cagrilintide (Primary) ; Ethinylestradiol/levonorgestrel; Paracetamol
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 20 Mar 2020 Status changed from active, no longer recruiting to completed.
- 07 Jan 2020 Planned End Date changed from 25 May 2020 to 9 Mar 2020.
- 07 Jan 2020 Planned primary completion date changed from 25 May 2020 to 9 Mar 2020.